Experts say China’s antimonopoly efforts continue to increase in efficiency and strength with nearly $300 million in regulatory fines so far this year, and those efforts are not expected to slow down.
According to reports, China has issued about $294 million in antitrust fines so far this year. Targets of these penalties include various Japanese auto parts manufacturers and various domestic insurers fined for anticompetitive conduct last month.
Insiders say China’s next phase in competition regulation will be to crack down on administrative monopolies – an effort that will likely include focus on the practice of using administrative power to harm competition.
China, which implemented its Anti-Monopoly Law in 2008, has been under fire in recent months for what some critics say is biased antitrust enforcement against foreign conglomerates. But experts say the coming months and years will likely show a more fair regulatory environment as it moves on to its second phase of regulation.
The first phase had authorities focus on monopolistic agreements, abuse of dominance and market concentration.
Full content: Want China Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Athletes File New Objections to NCAA’s $2.8 Billion Settlement Proposal
May 15, 2025 by
CPI
TikTok Charged by EU Over Alleged Breach of Digital Services Act
May 15, 2025 by
CPI
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas